<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Population Health</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/34B42FA8-0AC6-429B-AC54-D668F91213B9"><gtr:id>34B42FA8-0AC6-429B-AC54-D668F91213B9</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Howick</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800055"><gtr:id>80855ED1-575A-4513-94E4-119E4FE4FD8C</gtr:id><gtr:title>Pragmatic Evidence-Based Medicine: closing the implementation gap by promoting 'user-friendly' evidence</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800055</gtr:grantReference><gtr:abstractText>When a patient visits his doctor with a sore back, he wants to know whether the experimental intervention is better than the best existing intervention. This information is best obtained in an ?active controlled trial?. Yet, current wisdom has it that the best way to measure effectiveness is in a placebo controlled trial. My thesis examined the arguments that placebo controls are methodologically superior to active controls, and found them to be wanting - the apparent tension between good methods and usefulness is largely illusory. I intend to expand my thesis results in two ways. First, I will conduct social research into what patients/clients, practitioners, and policy makers regard as ?user-friendly? evidence, i.e. evidence that would be easy to put into practice. Second, I intend to investigate the methods for comparing the experimental intervention with all available interventions for a given ailment (rather than just one or two). The impact of my project, both in medical and social science research, could be to have an immediate effect on the delivery and uptake of the most effective interventions.</gtr:abstractText><gtr:technicalSummary>Objective I. Disseminate of my thesis findings to methodological and medical , and social intervention communities.
My doctoral and proposed extension of my doctoral work are both of particular interest to both the MRC and the ESRC. In particular my work will be able to inform any revisions of the ESRC?s Research Methods Programme, and will contribute to the MRC?s Methodology Research Programme.
An ?active? controlled trial is one that compares the experimental intervention with existing treatment. A placebo controlled trial is one that compares the experimental intervention with a placebo, or ?sham? intervention (i.e. sugar pill). Placebo controlled trials are regarded as methodologically superior to active controlled trials (Temple 2000; ICH E10 2000), but active-controlled trials are more ?user-friendly?, since they help the used decide between two or more available alternatives. My investigation concluded that the arguments for the methodological superiority of placebo over active controls are on the whole wanting. The importance of my work for the methodology of social science and medicine, where placebo controls are often difficult to design, is clear.

Objective II: (Thesis Extension) How do the relevant groups in society define user-friendly evidence
The arguments for the superiority of placebo controlled trials are made mostly by statisticians and researchers. It would be interesting to know whether potential users (i.e. patients), practitioners, and policy makers regard the information gained from active controlled trials to be more practically useful. In this section of my research I will conduct a small pilot study consisting of semi-structured interviews of patients, practitioners, policy makers, as well as statisticians and clinical researchers. I will use the results of this study to guide a methodological analysis of indirect comparisons of competing interventions.

Objective III: (Thesis Extension): Maximally User-Friendly Evi useful than simple active controlled trials, studies that compare all available interventions for a given ailment are more useful than studies that compare only two or three interventions. Such a study would providee way to accomplish this is to make ?indirect comparisons? of the effectiveness of each intervention trials that have already been accomplished (Glenny, Altman, et al: 2005). Beyond a few notable examples (Caldwell et al: 2005) the potentially useful indirect comparisons have few advocates and are rarely done. Further, indirect comparisons are regarded as methodologically problematic, not least of all because the populations could be different across trials. I propose to analyze methodological and empirical problems with indirect comparisons of all available interventions.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>184579</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Primary Care Health Sciences</gtr:department><gtr:description>Oxford Centre for Evidence-Based Medicine Levels of Evidence Working Group</gtr:description><gtr:id>D6D51B11-9FBD-4ACF-A32A-1ED7B267B702</gtr:id><gtr:impact>1. (forthcoming) New OCEBM Table of Evidence (beta version available: http://www.cebm.net/index.aspx?o=5653)
2. (forthcoming) Publication of Table and Introductory Document (BMJ or EBM Journal).
3. (as a more direct part of my postdoctoral fellowship): publication of part of the background document as a manifesto for 'user friendly evidence'.</gtr:impact><gtr:outcomeId>sEXyge6qehC-1</gtr:outcomeId><gtr:partnerContribution>Paul was a chair of the consensus meeting and participated actively in the development of the Table and supporting documents.</gtr:partnerContribution><gtr:piContribution>I recently organized an international group of experts on evidence to revise the Oxford Centre for Evidence-Based Medicine Evidence Table. His role involved mediating between diverging positions and coming up with documents that all members of the group endorsed. The group included:

Professor Paul Glaziou
Dr. Carl Heneghan
Hazel Thornton
Professor Alessandro Liberatti (Modena, Italy)
Dr. Ivan Moschetti (Italian Cochrane Centre)
Professor Patricia Greenhalgh</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Placebo Working Group</gtr:description><gtr:id>68AE4A61-501E-4E11-B859-8CECEBE05F67</gtr:id><gtr:impact>1. Survey of placebo use among UK general practitioners (Jeremy Howick as lead author, in press).
2. Systematic review of placebo effects compared with treatment effects across different conditions (Jeremy Howick as lead author, in press).</gtr:impact><gtr:outcomeId>RRhzBg28k8v-1</gtr:outcomeId><gtr:partnerContribution>1. Survey of placebo use among UK general practitioners (Jeremy Howick as lead author, in press).
2. Systematic review of placebo effects compared with treatment effects across different conditions (Jeremy Howick as lead author, in press).</gtr:partnerContribution><gtr:piContribution>1. Survey of placebo use among UK general practitioners (Jeremy Howick as lead author, in press).
2. Systematic review of placebo effects compared with treatment effects across different conditions (Jeremy Howick as lead author, in press).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Johns Hopkins Bloomberg School of Public Health</gtr:department><gtr:description>BIOLOGICAL MECHANISMS IN EVIDENCE-BASED MEDICINE</gtr:description><gtr:id>1557FFAD-9E5F-4821-A53E-13D0DD58E283</gtr:id><gtr:impact>(CONFIDENTIAL UNTIL PUBLISHED)</gtr:impact><gtr:outcomeId>3C3611BA762-1</gtr:outcomeId><gtr:partnerContribution>I PROVIDED EXPERTISE ON THE EVIDENTIAL ROLE OF MECHANISMS TO BENCH RESEARCHERS.</gtr:partnerContribution><gtr:piContribution>I PROVIDED EXPERTISE ON THE EVIDENTIAL ROLE OF MECHANISMS TO A PANEL AT JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH (BALTIMORE, MARYLAND).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cleveland Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Lerner Research Institute</gtr:department><gtr:description>International Point of Care Testing Working Group</gtr:description><gtr:id>8A74BDB8-6615-4D82-A926-D6B0243C8E61</gtr:id><gtr:impact>International survey of point of care testing use and desire for use.</gtr:impact><gtr:outcomeId>iowTzpYzs9x-1</gtr:outcomeId><gtr:partnerContribution>Survey of UK, American, Dutch, and Australian general practitioners regarding their use of, and desire for, various point of care tests.</gtr:partnerContribution><gtr:piContribution>Survey of UK, American, Dutch, and Australian general practitioners regarding their use of, and desire for, various point of care tests.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Translation of OCEBM Levels of Evidence into French</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5C713234-5EC7-4CFC-8757-EDF5DD26173F</gtr:id><gtr:impact>Translation of the OCEBM Levels of Evidence, and associated documents (Introductory Document, Background Document) into French.

Reaching french audience, improving quality of evidence internationally.</gtr:impact><gtr:outcomeId>awJTrhcY56L</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Patient Panel</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D351E8AF-648C-47FD-9E48-465AC4D2E3D9</gtr:id><gtr:impact>I have a team of patient/public representatives with whom I consult on a regular basis for my placebo research.

Improving research quality, making research relevant to real patients, involving members of the public.</gtr:impact><gtr:outcomeId>iskqQ5EuZyG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CEBM Mailing List</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EF37AB29-C66D-4B58-9584-7E232A3A622D</gtr:id><gtr:impact>Over 50 people responded to a call for feedback on the beta version of the new OCEBM Table of Evidence. I (Dr. Jeremy Howick) monitored the list and took all feedback into account.

Doctors, patients and policy makers commented that the new Table would help them make better-informed care decisions.</gtr:impact><gtr:outcomeId>pNQe8zvwC5o</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4F2A7EA7-4546-422D-B700-C3419059E8AE</gtr:id><gtr:impact>10 November 2015. &amp;quot;Why it is ethical to prescribe placebos in Clinical Practice&amp;quot;. Oxford Caf&amp;eacute; Scientifique. Oxford, UK.

14 October 2015. &amp;quot;Why it is ethical to prescribe placebos in Clinical Practice&amp;quot;. Bath Science Caf&amp;eacute;. Bath, UK.</gtr:impact><gtr:outcomeId>56dd9c7405f088.20142905</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Blog on www.trusttheevidence.net</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>72A72688-B41D-4373-BE29-4FD115C62610</gtr:id><gtr:impact>The OCEBM Website gets 2 million hits per year.

Open access, easily understood information about relevant topics.</gtr:impact><gtr:outcomeId>Dz8tuxefUYu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Publishing in Lay Press</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8FEE2A0B-9B7D-4CED-965C-36AADB0AD351</gtr:id><gtr:impact>Several newsagents, including Reuters and the Wall Street Journal reported the results of a paper on which I was the senior author ('What's in a Placebo')

Our aim with the paper was to change policy regarding revealing 'placebo' ingredients in the reports of clinical trials. The response to the paper was positive, and we expect that the next incarnation of the CONSORT Statement will take our findings into account.</gtr:impact><gtr:outcomeId>QBtStGAEaaL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Medical Association Dawkins and Strutt</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>375DAE7E-07D4-4616-B804-D7790CBC3671</gtr:id><gtr:outcomeId>58c1935b2e46f2.91857626</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institute for Health Research NSPCR Non Clinical Research Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>9BA265C9-CC8C-49CB-BC63-E357DE18CC70</gtr:id><gtr:outcomeId>jEMqMH3xZhY</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Mechanisms in Clinical Research</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EDBEF08C-B9FA-44A2-9B0E-B36E4CD530A9</gtr:id><gtr:outcomeId>hnSHksEtSiT</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Setting up centres for evidence-based medicine (EBM) in Lithuania and Uganda</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A36F12C5-F249-41D6-AF30-68C7E3116C67</gtr:id><gtr:impact>Based on my EBM expertise, specifically my ability to translate it for new audiences, I have participated in the founding of centres for EBM in Lithuania and Uganda.</gtr:impact><gtr:outcomeId>58c194985b1c55.03906564</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/25955430</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MEMBER OF THE GRADE WORKING GROUP</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>608D8500-74AE-4104-8971-23C9D99165EA</gtr:id><gtr:outcomeId>FB14F856FFB</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>OCEBM TABLE OF EVIDENCE 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F29F2F79-9CE1-4593-B250-8627B7E25578</gtr:id><gtr:impact>The OCEBM Levels of Evidence is widely used by patients, caregivers, and policy-makers. The revised version (forthcoming December 2010) is easier to use and the feedback from all stakeholders has been positive.</gtr:impact><gtr:outcomeId>rwRyoYvGFxX</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Producing Guidelines on the use of mechanistic evidence</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>6D1E929A-D5BD-4391-AD3C-816B3074BC04</gtr:id><gtr:impact>Based on my evidence-based medicine (EBM) expertise--specifically my critique of the EBM refusal to consider evidence from mechanisms, I am a member of a panel with the Dutch Health Ministry to produce guidelines, which I have drafted.</gtr:impact><gtr:outcomeId>58c1942750f7f5.78491918</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>I HAVE SUCCESSFULLY BRIDGED THE GAP BETWEEN MEDICINE, PHILOSOPHY, AND SOCIAL SCIENCE. MY WORK HAS BEEN PUBLISHED IN BOTH THE MEDICAL AND PHILOSOPHICAL LITERATURE, I HAVE PRESENTED MY WORK TO BOTH DISCIPLINES, AND I HAVE BEEN INVITED, AS AN EXPERT, TO CONTRIBUTE TO DEBATES IN BOTH FIELDS.</gtr:description><gtr:id>6A3C3F34-E67A-4A68-93EA-35ECF8D71EA6</gtr:id><gtr:impact>I HAVE DEMONSTRATED THAT INTER-DISCIPLINARY WORK IS BOTH POSSIBLE, AND FRUITFUL. I'VE INCREASED THE IMPACT OF PHILOSOPHICAL WORK, AND ALSO CONTRIBUTED TO THE EBM 'SYSTEM' OF EVIDENCE.</gtr:impact><gtr:outcomeId>3B707D45249</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CRITICAL THINKING FOR MEDICAL RESEARCH</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>95225473-CA82-4B03-B546-4BF0E634C383</gtr:id><gtr:title>Jeremy Howick: The philosophy of evidence-based medicine</gtr:title><gtr:parentPublicationTitle>Theoretical Medicine and Bioethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f10013cdff9e484e05a8562b7504916b"><gtr:id>f10013cdff9e484e05a8562b7504916b</gtr:id><gtr:otherNames>Bluhm R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>978-1405196673</gtr:isbn><gtr:outcomeId>ACoHz5dY66N</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D03F5FEA-BE67-425C-A6A3-51897CF93C51</gtr:id><gtr:title>If children understand drawing straws and flipping coins, research participants can understand randomization.</gtr:title><gtr:parentPublicationTitle>The American journal of bioethics : AJOB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1526-5161</gtr:issn><gtr:outcomeId>886F16D2E3E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5E3C8FC-B446-4AC1-9846-02C3B3362055</gtr:id><gtr:title>Reviewing the unsubstantiated claims for the methodological superiority of 'placebo' over 'active' controlled trials: reply to open peer commentaries.</gtr:title><gtr:parentPublicationTitle>The American journal of bioethics : AJOB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1526-5161</gtr:issn><gtr:outcomeId>608DE4B6C4D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50747FBD-17E6-4564-8CFE-E2250E5F6CA1</gtr:id><gtr:title>Exposing the Vanities-and a Qualified Defense-of Mechanistic Reasoning in Health Care Decision Making</gtr:title><gtr:parentPublicationTitle>PHILOSOPHY OF SCIENCE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9431a04deab06beeff1d21cea74ffa44"><gtr:id>9431a04deab06beeff1d21cea74ffa44</gtr:id><gtr:otherNames>Howick Jeremy</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0031-8248</gtr:issn><gtr:outcomeId>rSZH3BodyNn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27679C67-D72B-4764-92F7-B1BB89EB4ECA</gtr:id><gtr:title>The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>6F32EC4FDEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E90B7A3B-2FD0-4FDC-A9B5-3276AC126F02</gtr:id><gtr:title>Questioning the methodologic superiority of 'placebo' over 'active' controlled trials.</gtr:title><gtr:parentPublicationTitle>The American journal of bioethics : AJOB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1526-5161</gtr:issn><gtr:outcomeId>67B6D215528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F9C97CC-D840-4AEE-B5AD-5CD083FAFBEE</gtr:id><gtr:title>Placebo misery. Escaping from placebo prison.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>B3FEADB0A29</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A258D3B2-316D-40B5-B8C7-1D295FCD9D1A</gtr:id><gtr:title>Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Table of Evidence (Background Document)</gtr:title><gtr:parentPublicationTitle>www.cebm.net</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c0088a19488ac3d3399af50207f5fd"><gtr:id>d6c0088a19488ac3d3399af50207f5fd</gtr:id><gtr:otherNames>Howick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>B1ZiiAqJ3Dy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4454D394-3A55-4FC4-B125-52CC698EF70A</gtr:id><gtr:title>Exposing the Vanities-and a Qualified Defense-of Mechanistic Reasoning in Health Care Decision Making</gtr:title><gtr:parentPublicationTitle>Philosophy of Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_55f9849849abfda8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB76FF08-F72A-4AD1-A3A3-7749B178CE51</gtr:id><gtr:title>Evidence-based mechanistic reasoning.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>nwFuD3ZqV4F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C253F59-D607-4F06-9208-DA8071CC8D56</gtr:id><gtr:title>Can understanding mechanisms solve the problem of extrapolating from study to target populations (the problem of 'external validity')?</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6bba35684c592203c3398e72f10a13"><gtr:id>bd6bba35684c592203c3398e72f10a13</gtr:id><gtr:otherNames>Howick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>pm_13398_28_23481429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5BD8BC2-FC6B-444D-B708-7A8A2D0977C1</gtr:id><gtr:title>The Oxford 2011 Levels of Evidence&amp;quot;. Oxford Centre for Evidence-Based Medicine</gtr:title><gtr:parentPublicationTitle>www.cebm.net</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/662c92c7846afe4f9b20ebf8a7f64527"><gtr:id>662c92c7846afe4f9b20ebf8a7f64527</gtr:id><gtr:otherNames>OCEBM Levels of Evidence Working Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>d4ZqfRXq41H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E73290C-B172-47C7-AE3D-A4AEB763617E</gtr:id><gtr:title>Introduction to the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Table of Evidence</gtr:title><gtr:parentPublicationTitle>www.cebm.net</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/429fe922dc52d8cde88399f81792524e"><gtr:id>429fe922dc52d8cde88399f81792524e</gtr:id><gtr:otherNames>Howick, Jeremy</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>JGT7R342xMK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE1BB7EB-7F60-4BFE-B75B-54F0BA5281F0</gtr:id><gtr:title>What's in placebos: who knows? Analysis of randomized, controlled trials.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2ece58d63f01a84c83f6045ffb04ea7"><gtr:id>c2ece58d63f01a84c83f6045ffb04ea7</gtr:id><gtr:otherNames>Golomb BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>oQcxU2kqZY9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800055</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>